Abstract:Cardiac remodelling is a common pathophysiological process in the development of various cardiovascular diseases, but there is still a lack of effective interventions. Tumour necrosis receptor-associated factor 7 (TRAF7) belongs to the tumour necrosis factor receptor-associated factor family and plays an important role in biological processes. Previous studies have shown that TRAF7 mutations lead to congenital defects and malformations of the heart. However, the molecular mechanisms of TRAF7 in the underlying pathogenesis of pathological cardiac hypertrophy remain unknown. We aim to study the molecular mechanisms and effects of TRAF7 in cardiac remodelling and whether it has the potential to become a therapeutic target for cardiac remodelling. The pressure overload–induced cardiac hypertrophy model in mice was established via transverse aortic constriction (TAC) surgery, and cardiomyocytes were treated with phenylephrine (PE) to induce hypertrophic phenotype. Levels of cardiac dysfunction and remodelling were measured with echocardiography and tissue or cell staining. RNA sequencing, western blot, qRT–PCR, co-immunoprecipitation, and in vivo ubiquitination assays were used to explore the molecular mechanisms. The results showed that the expression of TRAF7 increased gradually during the development of hypertrophy. Accordingly, TRAF7 significantly exacerbated the PE-induced enlargement of primary neonatal Sprague-Dawley rat cardiomyocytes, whereas TRAF7 knockdown alleviated the hypertrophic phenotype in primary cardiomyocytes. Cardiac-specific overexpression of TRAF7 accelerated hypertrophic phenotype in mice and cardiac-specific Traf7 conditional knockout mice improved hypertrophic phenotype induced by TAC. Mechanistically, TRAF7 directly interacted with apoptosis signal-regulating kinase-1 (ASK1) and promoted ASK1 phosphorylation by mediating the K63-linked ubiquitination of ASK1 in response to PE stimulation, which then promoted ASK1 activation and downstream signalling during cardiac hypertrophy. Notably, the pro-hypertrophic effect of TRAF7 was largely blocked by GS4997 in vitro and cardiac-specific Ask1 conditional knockout in vivo . In summary, we identified TRAF7 as an essential regulator during cardiac hypertrophy, and modulation of the regulatory axis between TRAF7 and ASK1 could be a novel therapeutic strategy to prevent this pathological process. A schematic diagram of the molecular mechanisms underlying tumour necrosis receptor-associated factor 7 (TRAF7)-regulated cardiac hypertrophy. Under hypertrophic stimulation, reactive oxygen specices (ROS)-triggered TRAF7 expressing binds to the apoptosis signal-regulating kinase-1 (ASK1) through its WD40 repeats domain and applies the ring domain to promote the ubiquitination of lys1064 in ASK1 via the K63 ubiquitin chain, thereby promoting ASK1 phosphorylation and then activating JNK/p38 axis in cardiomyocytes.

Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes

Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats

Cardiac-specific Overexpression of Farnesyl Pyrophosphate Synthase Induces Cardiac Hypertrophy and Dysfunction in Mice.

Inhibition of Farnesyl Pyrophosphate Synthase Improves Pressure Overload Induced Chronic Cardiac Remodeling

Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.

Cardiomyocytes Deficiency of SENP1 Promotes Myocardial Fibrosis Via Paracrine Action

Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction.

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Follistatin-Like 1 Attenuates Ischemia/Reperfusion Injury in Cardiomyocytes via Regulation of Autophagy.

RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1

Activated FMS‐like Tyrosine Kinase 3 Ameliorates Angiotensin II‐induced Cardiac Remodelling

Transcription Factor EB (TFEB) Improves Ventricular Remodeling after Myocardial Infarction by Inhibiting Wnt/β-catenin Signaling Pathway

Inhibition of Mitofusin-2 Promotes Cardiac Fibroblast Activation via the PERK/ATF4 Pathway and Reactive Oxygen Species

FGF21 improves ventricular remodeling in TAC induced heart failure rats

[Expression of connective tissue growth factor in cardiomyocyte of young rats with heart failure and benazepril intervention].

Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice

Increased CPT1a expression is a critical cardioprotective response to pathological stress that suppresses gene programs for remodeling and enables rescue by gene transfer

Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP

Cardiac tumour necrosis factor receptor-associated factor 7 mediates the ubiquitination of apoptosis signal-regulating kinase 1 and aggravates cardiac hypertrophy

LITAF acts as a novel regulator for pathological cardiac hypertrophy

TRAF Family Member 4 Promotes Cardiac Hypertrophy Through the Activation of the AKT Pathway